利拉鲁肽治疗2型糖尿病合并骨质疏松患者血清趋化素水平和骨密度变化的研究

Influence of Liraglutide on serum Chemerin and bone mineral density in type diabetic patients with osteoporosis

目的 观察T2DM合并骨质疏松(OP)患者经利拉鲁肽治疗后血清趋化素(Chemerin)和骨密度(BMD)水平的变化.方法 选取2017年1~12月于我院内分泌科就诊的T2DM合并骨质疏松患者(OP组)72例、单纯T2DM患者(T2DM组)70例及同期我院健康体检者(NC组)70名,比较各组血清Chemerin和BMD水平.OP组接受利拉鲁肽治疗12周,比较治疗前、治疗12周时及停药12周后血清Chemerin和BMD水平.结果 OP组BMI、FPG、HbA1c、肿瘤坏死因子α(TNF-α)、白介素6(IL-6)及Chemerin均高于NC、T2DM组,BMD低于NC、T2DM组[(0.91±0.07)vs(1.18±0.07)vs(1.05±0.08)g/cm2,P<0.05].与基线相比,OP组治疗12周后和停药12周后BMI、FPG、HbA1c、LDL-C、TNF-α、IL-6、Chemerin 均降低,BMD 升高(P<0.01).与治疗 12 周后比较,停药 12 周后FPG、IL-6、Chemerin 升高,BMD 降低(P<0.01).结论 利拉鲁肽能降低 Chemerin 水平,提高BMD水平,是治疗T2DM合并OP的有效药物.

Objective To investigate the influence of Liraglutide on serum Chemerin and bone mineral density(BMD)in T2 DM patients with osteoporosis.Methods A total of 72 T2DM patients with osteoporosis(OP group),70 T2DM patients(T2DM group)were recruited in this study from the Department of Endocrinology of our hospital from January to December at 2017.At the same time,70 healthy subjects were recruited as normal control(NC)group.The levels of Chemerin and BMD were detected and compared among the three groups.OP group received Liraglutide treatment and followed up for 12 weeks.The levels of Chemerin and BMD were compared before,after treatment for 12 weeks and after discontinue of Liraglutide.Results The levels of BMI,FPG,HbA1 c,TNF-α,IL-6 and Chemerin were higher and the BMD[(0.91±0.07)vs(1.18±0.07)vs(1.05±0.08)g/cm2]was lower in OP group than in NC and T2DM group(P<0.05).The levels of BMI,FPG,HbA1c,LDL-C,TNF-α,IL-6,and Chemerin were reduced,while BMD were increased after treatment for 12 weeks and discontinue of Liraglutide for 12 weeks(P<0.01).FPG and IL-6 were increased,while MBD was decreased after discontinue of Liraglutide 12-week compared with after treatment for 12 weeks(P<0.01).Conclusion Liraglutide could reduce Chemerin level,increase BMD,and it maybe an effective drugs for the treatment of T2DM combined with osteoporosis.